Bicycle Therapeutics PLC (BCYC): Total Assets
$717.60M
As of 2025-12-31
$606.58M
As of 2026-06-30
+20.5%
3-year compound annual growth
+34.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $717.60M | -25.0% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $956.87M | +60.7% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $595.34M | +45.0% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $410.61M | -14.4% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $479.79M | +197.7% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $161.15M | +46.2% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $110.19M | +35.0% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $81.63M | n/a | 2020-03-10, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $717.60M | -25.0% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $257.59M | +116.2% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $899.42M | +21.1% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $1.36B | -0.3% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $57.15M | -3.5% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $151.57M | +25.7% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $738.36M | -2.9% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $68.92M | -37.7% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $92.11M | +21.0% |
Compare BCYC, ASMB, VRDN, ABCL side by side · Screen every company in Pharmaceutical Preparations ↗